Business context and reporting period
This Form 10-Q covers the three months ended March 31, 2018. At quarter-end, Amneal Pharmaceuticals, Inc. was Atlas Holdings, Inc., a shell company formed to facilitate the combination of Impax Laboratories and Amneal Pharmaceuticals LLC. It had no operating activities, material assets, or material liabilities before the transaction closed on May 4, 2018. Accordingly, these are shell-company results, not results for the combined pharmaceutical business.
Financial results and liquidity
- The statements show dashes for revenue, operating expenses, income taxes, net loss, cash flows, assets, and liabilities; the filing does not provide clear numerical values for these lines. Management states the company had no revenues or operating earnings as of March 31.
- Margins, debt, and operating cash flow are not meaningful for this reporting entity and period. The company reported no off-balance-sheet arrangements and no significant market risks.
- Equity consisted of 1,000 common shares issued to Impax, $10 of common stock, and a $10 stockholder receivable, resulting in no reported stockholders’ equity.
- Balance-sheet figures are also shown as dashes at December 31, 2017; the filing does not provide a substantive prior-period operating comparison.
Material changes and subsequent events
- On May 4, 2018, the combination with Impax and Amneal LLC closed; the company changed its name to Amneal Pharmaceuticals, Inc. and began trading as AMRX on the NYSE on May 7.
- After closing, Amneal LLC entered into a term loan facility of up to $2.7 billion, maturing May 4, 2025, and an asset-based revolving credit facility of up to $500 million, maturing May 4, 2023. Term-loan proceeds helped fund the transaction, repay existing debt, and pay related fees and expenses.
- On May 7, Amneal LLC agreed to acquire 98% of Gemini Laboratories for $40.0 million cash, a $77.2 million six-month promissory note, and assumed liabilities. The filing identifies this as a related-party transaction.
- These subsequent events did not affect the March 31 financial statements.
Outlook, risks, and contingencies
- The filing provides no financial guidance or operating outlook for the combined company.
- Two securities class actions alleging omissions and misstatements in transaction-related disclosures were dismissed by court order on April 5, 2018. Plaintiffs could petition for attorneys’ fees and expenses by June 1, 2018.
- Management reported no material changes to previously disclosed risk factors. Disclosure controls were judged effective as of March 31, 2018; no material changes in internal control were reported.
Important facts for investors to verify
- Review subsequent filings for the combined company’s operating results, debt balances, liquidity, and integration costs; this quarter’s statements do not reflect the operating businesses.
- Verify the final funded amounts and terms of the term loan and revolving facility, including borrowing, repayment, and covenant details.
- Check the status and final consideration, including assumed liabilities, of the Gemini related-party acquisition.
- Check whether plaintiffs sought attorneys’ fees in the dismissed securities actions and the outcome of any such request.